Factor contributing to peak VO2 in idiopathic pulmonary fibrosis: in comparison with COPD

S. Arizono, O. Nishiyama, Y. Kondoh, T. Kimura, K. Kato, K. Kataoka, T. Ogawa, F. Watanabe, H. Taniguchi (Seto, Aichi, Japan)

Source: Annual Congress 2007 - Assessment and outcomes in non-COPD patients
Session: Assessment and outcomes in non-COPD patients
Session type: Electronic Poster Discussion
Number: 4507

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Arizono, O. Nishiyama, Y. Kondoh, T. Kimura, K. Kato, K. Kataoka, T. Ogawa, F. Watanabe, H. Taniguchi (Seto, Aichi, Japan). Factor contributing to peak VO2 in idiopathic pulmonary fibrosis: in comparison with COPD. Eur Respir J 2007; 30: Suppl. 51, 4507

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Limiting factors at maximal exercise in sarcoidosis and idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010


Exercise capacity in idiopathic pulmonary fibrosis and COPD
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010


Pulmonary emphysema and idiopathic pulmonary fibrosis: Is the pattern of exercise-induced oxygen desaturation same or different?
Source: Annual Congress 2010 - Gas exchange and paediatric exercise testing
Year: 2010

Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006

Pulmonary hypertension in idiopathic pulmonary fibrosis: correlation to pulmonary function and exercise parameters
Source: Eur Respir J 2007; 30: Suppl. 51, 607s
Year: 2007

Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013


Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Relationship between chronic dyspnoea and indices of disease severity in idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 150s
Year: 2001

Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020

Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017

Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015

Determinants of exercise limitation in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 107s
Year: 2005

Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis (IPF) with inspiratory muscle training
Source: Annual Congress 2007 - Assessment and outcomes in non-COPD patients
Year: 2007


Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Source: Eur Respir Rev 2011; 20: 195-200
Year: 2011



Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011



Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013

Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Year: 2011

A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015


Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF?
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009


Exercise-induced pulmonary hypertension in patients with idiopathic pulmonary fibrosis: effects of oxygen
Source: Eur Respir J 2007; 30: Suppl. 51, 607s
Year: 2007